These findings suggest that fruquintinib plus albumin-bound paclitaxel exhibits promising efficacy and manageable toxicity in anti-PD-1-refractory GC, warranting further exploration in combination strategies targeting alternative pathways. The gene discussed is PDCD1; the disease is gastric cancer.